| 0 (0%) | 01-14 09:37 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.89 |
1-year : | 5.23 |
| Resists | First : | 4.19 |
Second : | 4.48 |
| Pivot price | 3.86 |
|||
| Supports | First : | 3.73 | Second : | 3.1 |
| MAs | MA(5) : | 3.82 |
MA(20) : | 3.88 |
| MA(100) : | 4.84 |
MA(250) : | 4.64 |
|
| MACD | MACD : | -0.2  |
Signal : | -0.2 |
| %K %D | K(14,3) : | 38 |
D(3) : | 30.1 |
| RSI | RSI(14): 40.4 |
|||
| 52-week | High : | 6.32 | Low : | 3.27 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AVD ] has closed above bottom band by 40.1%. Bollinger Bands are 62.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.96 - 3.98 | 3.98 - 4 |
| Low: | 3.76 - 3.78 | 3.78 - 3.8 |
| Close: | 3.81 - 3.84 | 3.84 - 3.87 |
Tue, 13 Jan 2026
Analysis confirms benefit of nivolumab combo in teens with advanced Hodgkin lymphoma - Medical Xpress
Fri, 09 Jan 2026
Aviceda releases phase 2b topline data on AVD-104 for GA - Eyes On Eyecare
Fri, 19 Dec 2025
Durable 3-Year Superiority of N-AVD in Advanced Hodgkin Lymphoma - Targeted Oncology
Fri, 19 Dec 2025
N-AVD, BrECADD Win in Advanced Hodgkin Lymphoma Trials - Medscape
Mon, 15 Dec 2025
Aviceda Therapeutics reports positive phase 2b SIGLEC results for AVD-104 in geographic atrophy - Ophthalmology Times
Thu, 11 Dec 2025
Nivolumab/AVD Receives FDA Priority Review in Classical Hodgkin Lymphoma - CancerNetwork
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 28 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 8.5 (%) |
| Held by Institutions | 69.5 (%) |
| Shares Short | 710 (K) |
| Shares Short P.Month | 597 (K) |
| EPS | -3.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.61 |
| Profit Margin | -21.2 % |
| Operating Margin | -4.4 % |
| Return on Assets (ttm) | -1.7 % |
| Return on Equity (ttm) | -40.9 % |
| Qtrly Rev. Growth | 0.8 % |
| Gross Profit (p.s.) | 4.48 |
| Sales Per Share | 18.61 |
| EBITDA (p.s.) | 0.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | 36 (M) |
| PE Ratio | -0.97 |
| PEG Ratio | 0 |
| Price to Book value | 0.5 |
| Price to Sales | 0.2 |
| Price to Cash Flow | -62.84 |
| Dividend | 0.02 |
| Forward Dividend | 0 |
| Dividend Yield | 0.7% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|